SCYNEXIS, Inc. Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One
SCYNEXIS, Inc. (SCYX) had Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One of $27.90 million as of 2023-03-31, per its 10-Q filed 2023-05-10.
Discontinued › Notes › Debt and Equity Securities
us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount · last filed 2023-05-10
- 2023-03-31: Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $27.90M.
- 2022-09-30: Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $27.50M.
- 2019-12-31: Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $6.50M.
- 2018-12-31: Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $32.70M.
| Period end | Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One |
|---|---|
| 2023-03-31 | $27.90M 10-Q · filed 2023-05-10 |
| 2022-09-30 | $27.50M 10-Q · filed 2022-11-09 |
| 2019-12-31 | $6.50M 10-K · filed 2021-03-29 |
| 2018-12-31 | $32.70M 10-K · filed 2019-03-14 |
| 2017-12-31 | $32.40M 10-K · filed 2018-03-13 |
| 2017-03-31 | $35.00M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $22.93M 10-K · filed 2017-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |